diabetestalk.net

Diabetes Care 2018

These Developments In Diabetes Care Will Shape The Industry Next Year

These Developments In Diabetes Care Will Shape The Industry Next Year

How Medtronic's MiniMed 670G grows Production delays hobbled the June launch of Medtronic's hybrid closed-loop system. The technology has been hailed as a milestone because it's the first insulin pump that delivers insulin somewhat automatically. The system combines a continuous glucose monitor, an algorithm and a pump. They work together to measure and analyze glucose levels to adjust the amount of insulin delivered accordingly. Medtronic's system is considered a hybrid closed-loop because although the Guardian Sensor 3 and MiniMed 670G pump work together, they still require some patient input. For example, patients need to enter information about what they're eating and calibrate their pumps using fingerstick testing. The Food and Drug Administration approved the system in September 2016, months earlier than expected. Medtronic had recently introduced the MiniMed 630G system, meaning a number of patients had just purchased a new device. The number of people wanting the new system caused a spike in demand that slowed production, creating a backlog of people waiting to buy it. The slowdown weighed on Medtronic's total diabetes segment, which accounts for about 7 percent of its total revenue. The category declined 2 percent in constant currency last quarter. It rose 4 percent last fiscal year, which ended in April. The company does not break out the total diabetes segment revenue by category, but intensive insulin management represents the bulk of its sales. That group declined low single digits last quarter. Last fiscal year, it grew high single digits. Medtronic expects to ramp up production in its fourth quarter, which ends in April. Analysts expect fixing the slowdown will help the diabetes segment grow again. Impact of Abbott's FreeStyle Libre Abbott launched its Fr Continue reading >>

American Diabetes Association® Releases 2018 Standards Of Medical Care In Diabetes, With Notable New Recommendations For People With Cardiovascular Disease And Diabetes

American Diabetes Association® Releases 2018 Standards Of Medical Care In Diabetes, With Notable New Recommendations For People With Cardiovascular Disease And Diabetes

ARLINGTON, Va., Dec. 8, 2017 /PRNewswire/ -- Notable new recommendations in the 2018 edition of the American Diabetes Association's (ADA's) Standards of Medical Care in Diabetes (Standards of Care) include advances in cardiovascular disease risk management including hypertension; an updated care algorithm that is patient-focused; the integration of new technology into diabetes management; and routine screening for type 2 diabetes in high-risk youth (BMI >85th percentile plus at least one additional risk factor). The Standards of Care provide the latest in comprehensive, evidence-based recommendations for the diagnosis and treatment of children and adults with type 1, type 2 or gestational diabetes, strategies to improve the prevention or delay of type 2 diabetes, and therapeutic approaches that reduce complications and positively affect health outcomes. The Standards of Care are published annually and will be available online at 4:00 p.m. ET, December 8, 2017, and as a supplement to the January 2018 print issue of Diabetes Care. Experience the interactive Multichannel News Release here: Beginning in 2018, the ADA will update and revise the online version of the Standards of Care throughout the year with necessary annotations if new evidence or regulatory changes merit immediate incorporation. This will ensure that the Standards of Care provide clinicians, patients, researchers, health plans and policymakers with the most up-to-date components of diabetes care, general treatment goals and tools to evaluate the quality of care. The Standards of Care will also be available as a user-friendly and interactive app for both web and mobile devices in the spring of 2018. The app will allow clinicians to access the most up-to-date information conveniently and will include interac Continue reading >>

A Summary Of Ada’s New 2018 Standards Of Medical Care In Diabetes

A Summary Of Ada’s New 2018 Standards Of Medical Care In Diabetes

Comprehensive recommendations feature notable new recommendations for people with cardiovascular disease and diabetes. New recommendations in the 2018 edition of the American Diabetes Association’s (ADA’s) Standards of Medical Care in Diabetes (Standards of Care) include advances in cardiovascular disease risk management, including hypertension; an updated care algorithm that is patient-focused; the integration of new technology into diabetes management; and routine screening for type 2 diabetes in high-risk youth (BMI >85th percentile plus at least one additional risk factor). The Standards of Care provide the latest in comprehensive, evidence-based recommendations for the diagnosis and treatment of children and adults with type 1, type 2, or gestational diabetes, strategies to improve the prevention or delay of type 2 diabetes, and therapeutic approaches that reduce complications and positively affect health outcomes. The Standards of Care have been published in advance of a supplement to the January 2018 print issue of Diabetes Care. The Standards of Care are the primary resource for the optimal management of diabetes, and include updated guidelines for diabetes diagnosis, and for evidence-based prevention of diabetes and diabetes-related complications. A summary of the important changes in the 2018 edition are: Cardiovascular disease and diabetes Based upon the results of multiple cardiovascular outcome trials (CVOT), there are new treatment recommendations for adults with type 2 diabetes, suggesting a pathway for people with heart disease that, after lifestyle management and metformin, should include a medication validated to improve heart health. (Section 8, page S76, Table 9.4 and Figure 8.1, respectively) Four major, randomized controlled trials that compare Continue reading >>

Ada Releases 2018 Diabetes Care Guidelines

Ada Releases 2018 Diabetes Care Guidelines

The American Diabetes Association (ADA) released its 2018 Standards of Medical Care in Diabetes this week, and several of the new recommendations involved older adults with co-morbidities, including those with cardiovascular disease or hypertension as well as diabetes. Among the changes in the guidelines relevant to older adults: Based upon the results of multiple cardiovascular outcome trials (CVOT), there are new treatment recommendations for adults with type 2 diabetes, suggesting a pathway for people with heart disease that, after lifestyle management and metformin, should include a medication validated to improve heart health. A new table outlines the data from recent CVOT studies, and a new figure details our recommendations based on those CVOT studies. A new algorithm illustrating the recommended antihypertensive treatment approach for adults with diabetes and confirmed hypertension (blood pressure ≥140/90 mmHg) has been added. Also new this year is the recommendation that all hypertensive patients with diabetes monitor their blood pressure at home to help identify potential discrepancies between office vs. home blood pressure, and to improve medication-taking behavior. The immunization needs for people with diabetes were clarified and updated to more closely align with recommendations from the Centers for Disease Control and Prevention. A new section describes emerging evidence that specific glucose-lowADA releases 2018 diabetes care guidelinesering medications can delay the onset and progression of kidney disease. In addition, three new recommendations targeting older adults were added to highlight the importance of individualizing pharmacologic therapy to reduce the risk of hypoglycemia, avoid overtreatment and simplify complex regimens while maintaining pe Continue reading >>

The Pharmacist & Patient-centered Diabetes Care 2018

The Pharmacist & Patient-centered Diabetes Care 2018

The Pharmacist & Patient-Centered Diabetes Care 2018 The Pharmacist & Patient-Centered Diabetes Care 2018 The American Pharmacists Association will host8 offerings ofAPhA's The Pharmacist & Patient-Centered Diabetes Care certificate training program in 2018.Supported by an educational grant from Merck and Novo Nordisk, APhA will conduct these special programs for a nominal fee of$99to participate.Locations and dates arelisted below and registration will open on a rolling basis. Please revisit this page for more information as it is updated. Scroll below and click on the desired date/city/state. Click View Schedule to seeseminar date andlocation Select desired seminar date/ location and proceed through checkout Prior to purchasing this session, please verify that this is the seminar for which you would like to enroll $99 Program fee is non-refundableand you maynot switch sessions after purchase Once your purchase has been made, you can begin to study. Go toContinuing Education, My Training ,and scroll down to My Enrollments. At the live seminar, each participant who attends the entire seminar will be given an attendance code which has a shortexpiration date. Once redeemed and the post activities completed, the live credit can be claimed and a certificate can be printed. Please arrive at the program site by at least 7:30 am for sign-in. The program will begin promptly at 8:00 am. NOTE: Late arrivals and/or leaving early could jeopardize your credit for the live component. There is no partial credit. If you need to book your personal lodging, you can view the program address: UnderMy Meetingson yourMy Accountpage Some offerings do have a special hotel rate - if offered, it will be noted below. If a class is listed as CLOSED the program has reached its maximum capacity. If Continue reading >>

Ada’s 2018 Updates To Standards Of Medical Care In Diabetes

Ada’s 2018 Updates To Standards Of Medical Care In Diabetes

New guidelines address data-driven technology and humanizing diabetes care. The American Diabetes Association (ADA) just released its 2018 Standards of Medical Care in Diabetes. Since 1989, the organization has provided annual updates to keep current with research, technology, and treatments for both Type 1 and Type 2 Diabetes. The latest changes reflect an emerging reality for diabetes care in the twenty-first century: data-driven technology is increasingly integral in the management of the disease. sponsor The 2018 guide recognizes the enormous benefit of emerging technologies, such as continuous glucose monitoring (CGM) systems and automated insulin delivery systems. It provides more extensive-than-ever guidelines to providers on these technologies, and it expands recommendations for the use of such systems. For instance, the ADA now recommends the use of CGM for all adults with Type 1 Diabetes who are not achieving glycemic targets. (Previously, the technology was only recommended to persons 25 and above.) The ADA has also added text to inform providers about a recently approved intermittent (“flash”) CGM device and about CGM devices that no longer require manual confirmation of blood glucose for treatment decisions. Read “Five Quick-takes from the ADA 77th Scientific Sessions” There are suggestions for using analytics from devices to tailor and individualize treatment decisions. For instance, physicians are encouraged to use data to assess an individual’s hypoglycemic and hyperglycemic risks, and, in turn, adjust A1C goals. In addition to recognizing the value of such developments, the ADA is mindful that many patients today feel as though they are being scrutinized and/or reduced to a pile of statistics. Consequently, the 2018 manual includes extensive r Continue reading >>

Tandem Diabetes Care Announces Preliminary First Quarter 2018 Results

Tandem Diabetes Care Announces Preliminary First Quarter 2018 Results

Tandem Diabetes Care Announces Preliminary First Quarter 2018 Results April 10, 2018 08:30 AM Eastern Daylight Time SAN DIEGO--( BUSINESS WIRE )--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported select, unaudited and preliminary results for the quarter ended March 31, 2018. Pump shipments increased by 56 percent to approximately 4,400 pumps in the first quarter of 2018 from 2,816 pumps in the same period of 2017. Sales increased by 42 percent to approximately $27.0 million in the first quarter of 2018 from $19.0 million in the same period of 2017. The first quarter of 2017 benefited from $1.5 million in previously deferred sales that were recognized during the period1. As of March 31, 2018, the Company had approximately $81.9 million in cash, cash equivalents, short-term investments and restricted cash. This includes approximately $64.2 million in net proceeds from the equity financing completed in February 2018 and $6.5 million in net proceeds from warrants exercised in the first quarter of 2018. The Company anticipates that outstanding Series B warrants to purchase common stock will continue to be exercised before they expire on April 17, 2018. Continued high-demand for the t:slim X2 Insulin Pump drove our record first quarter sales, and supports our strategy of using modern, consumer-focused technology to improve the lives of people with diabetes, said Kim Blickenstaff, President and CEO. This strong commercial momentum allows us to continue leveraging our early infrastructure investments and positions us well to deliver upon our goals in 2018. First Quarter 2018 Earnings Conference Call The Company intends to report its first quarter 2018 financi Continue reading >>

Ada 2018 Standards Address Diabetes Drugs With Cv Benefit

Ada 2018 Standards Address Diabetes Drugs With Cv Benefit

ADA 2018 Standards Address Diabetes Drugs With CV Benefit The American Diabetes Association's annual guidelines for 2018 include new recommendations for use of glucose-lowering drugs with proven cardiovascular benefit in type 2 diabetes, optimization of diabetes care in elderly patients, and glucose screening of high-risk adolescents. The organization has also chosen to stick with its existing definition of hypertension in diabetes, of 140/90 mm Hg, in contrast to cardiology societies that have recently changed their guidance so that 130/80 mm Hg represents "stage 1 hypertension," including in diabetes. Probably the most anticipated and impactful new recommendation from the ADA calls for use of a glucose-lowering agent with proven cardiovascular benefit such as the glucagonlike peptide 1 (GLP-1) agonist liraglutide (Victoza Novo Nordisk) and/or mortality reduction such as that observed with the sodium glucose cotransporter-2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim/Lilly) in type 2 diabetes patients with established atherosclerotic cardiovascular disease (ASCVD) who don't meet glycemic targets with lifestyle modification and metformin. "We now have drugs that are not only indicated to improve glycemic control but that reduce cardiovascular risk and mortality. So, based on some of the [ cardiovascular-outcomes] trials , there are new recommendations for treatment of adults with type 2 diabetes who fail metformin therapy, if there's a background of atherosclerotic cardiovascular disease," the ADA's chief scientific, medical, and mission officer, William T Cefalu, MD, told Medscape Medical News. A new table outlines the data from recent cardiovascular-outcomes studies, and a new figure details the recommendations based on those (Section 8, page S97 Continue reading >>

Innovators From 17 Countries Vie For $250,000 In Cash And In-kind Support To Advance Diabetes Care In The 2018 Diabetes Innovation Challenge

Innovators From 17 Countries Vie For $250,000 In Cash And In-kind Support To Advance Diabetes Care In The 2018 Diabetes Innovation Challenge

Innovators From 17 Countries Vie for $250,000 in Cash and In-Kind Support to Advance Diabetes Care in the 2018 Diabetes Innovation Challenge Submissions include research to develop new insulin delivery technologies, therapeutics, diagnostics, and digital app-based tools to improve outcomes BOSTON, March 20, 2018 (GLOBE NEWSWIRE) -- T1D Exchange , a nonprofit research and collaboration organization dedicated to accelerating novel treatments to improve the care of people living with type 1 diabetes (T1D), today announced that 60 academic researchers and early stage companies from around the world have submitted entries for the 2018 Diabetes Innovation Challenge. Launched in 2016, the Diabetes Innovation Challenge is a world-wide competition to identify, nurture and fast-track innovative scientific and clinical solutions for diabetes. The 2018 Diabetes Innovation Challenge is presented by T1D Exchange with the generous support of lead sponsors The Leona M. and Harry B. Helmsley Charitable Trust and JDRF, along with the American Diabetes Association and Eli Lilly and Company. We are excited to see this level of interest, not only from the United States, but from 16 other countries from across the globe, said Dana Ball, executive director and co-founder of T1D Exchange. We see the Diabetes Innovation Challenge as a pivotal strategy to focus the best minds to advance breakthroughs to manage, treat, and perhaps even cure one of the most pressing health issues we face. In the U.S. alone more than 30 million people are living with diabetes with a total economic cost of more than $300 billion annually. The importance of accelerating new treatment and disease management strategies to improve the quality of life of people with diabetes and reduce the higher risk they face for stro Continue reading >>

A New Way For Diabetes Care Creating Health With More Freedom, Better Outcomes And Greater Value

A New Way For Diabetes Care Creating Health With More Freedom, Better Outcomes And Greater Value

Aetnas Health Section was established in 2014 to create in-depth news, analysis and perspectives on the changing health care landscape. The Health Section provides a deeper look at Aetnas efforts to transform the health care system, and our approach to building healthier communities, a healthier nation and a healthier world. Aetnas Health Section was established in 2014 to create in-depth news, analysis and perspectives on the changing health care landscape. The Health Section provides a deeper look at Aetnas efforts to transform the health care system, and our approach to building healthier communities, a healthier nation and a healthier world. A new way for diabetes care Creating health with more freedom, better outcomes and greater value A new way for diabetes care Creating health with more freedom, better outcomes and greater value Managing type 2 diabetes can be difficult. But the right planning, care and tools can make a big difference. Thats why Aetna is working with local doctors, nurses and other providers to transform health care. Click the graphic below and scroll to learn how Aetna is helping members receive the right care at the right time in the right place. Click the photo and scroll to see how value-based care can help you better manage type 2 diabetes. Continue reading >>

Review Of The Ada Standards Of Medical Care In Diabetes 2018 | Annals Of Internal Medicine | American College Of Physicians

Review Of The Ada Standards Of Medical Care In Diabetes 2018 | Annals Of Internal Medicine | American College Of Physicians

Author, Article, and Disclosure Information This article was published at Annals.org on 3 April 2018. St. Mark's Hospital and St. Mark's Diabetes Center, Salt Lake City, Utah (J.J.C.) UND School of Medicine and Health Sciences, Grand Forks, North Dakota (E.L.J.) Touro University College of Osteopathic Medicine, Vallejo, California (J.H.S.) Utah State University, Taylorsville, Utah (L.P.) Acknowledgment: The authors thank Sarah Bradley; Matt Petersen; and Erika Gebel Berg, PhD, for their invaluable assistance in the reviewing and editing of this manuscript. The full Standards of Medical Care in Diabetes2018 was developed by the ADA's Professional Practice Committee: Rita R. Kalyani, MD, MHS (Chair); Christopher Cannon, MD; Andrea L. Cherrington, MD, MPH; Donald R. Coustan, MD; Ian de Boer, MD, MS; Hope Feldman, CRNP, FNP-BC; Judith Fradkin, MD; David Maahs, MD, PhD; Melinda Maryniuk, Med, RD, CDE; Medha N. Munshi, MD; Joshua J. Neumiller, PharmD, CDE; and Guillermo E. Umpierrez. ADA staff support includes Erika Gebel Berg, PhD; Tamara Darsow, PhD; Matt Petersen; Sacha Uelmen, RDN, CDE; and William T. Cefalu, MD. Disclosures: Dr. Chamberlain reports other support from Novo Nordisk, Sanofi Aventis, Janssen, and Merck outside the submitted work. Dr. Johnson reports personal fees from Novo Nordisk, Medtronic, and Sanofi outside the submitted work. Dr. Rhinehart reports employment with and stock ownership in Glytec. Dr. Shubrook reports personal fees from Novo Nordisk, Lilly Diabetes, and Intarcia outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-0222 . Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that he Continue reading >>

The 3cs Of Diabetes Technology Will Revolutionize Diabetes Care 2018. From Idf Meeting Dec. Report

The 3cs Of Diabetes Technology Will Revolutionize Diabetes Care 2018. From Idf Meeting Dec. Report

The 3Cs of Diabetes Technology Will Revolutionize Diabetes Care 2018. From IDF Meeting Dec. Report The 3Cs of Diabetes Technology Will Revolutionize Diabetes Care 2018. From IDF International Diabetes Federation Meeting 4-8 Dec Report Diabetes technology is the new kid on the block when it comes to the management of type 1 and type 2 diabetes, but for most doctors and patients it's still an enigma, and only a small minority of people with diabetes in developed countries know anything about itor are actually using it. In an attempt to demystify the topic, Adam Brown, head of diabetes technology and digital health atClose Concerns a diabetes news and education website and a type 1 diabetes patient himself, with 50,000+ hours of experience using a continuous glucose monitor (CGM), gave a fascinating and highly informative talk at theInternational Diabetes Federation (IDF) Congress 2017recently, entitled: "Diabetes tools and apps: What's new, what works, and what do patients really want?" Brown broke down existing technology into three categories that he believes are starting to show real promise, which he christened"the 3Cs" CGM, coaching/remote care, and clever insulin delivery. What people with diabetes really want, he said, is "better outcomes time in range and HbA1c. They want to sleep better and have a happier life and mind-set." Brown has written a book,Bright Spots & Landmines: TheDiabetes Guide I Wish Someone Had Handed Me, which is available fromdiaTribe.org/BrightSpotsas a free PDF which shares the food, mind-set, exercise, and sleep strategies he has personally learned over the many years of dealing with his diabetes."Many endocrinologists have told us they are giving the book to patients in their clinic with diabetes," he told Medscape. Patients also want diab Continue reading >>

What To Know About The Ada's 2018 Standards Of Medical Care If You Have Diabetes

What To Know About The Ada's 2018 Standards Of Medical Care If You Have Diabetes

Living with poorly controlled blood sugar levels may lead to potentially serious health complications for people with diabetes — including diabetic neuropathy, diabetic retinopathy, amputations, depression, sexual issues, heart disease, stroke, and even death. But luckily, if you have type 1 or type 2 diabetes, managing your diet, lifestyle, and treatment well can help you stabilize blood sugar and ultimately reduce the risk of these potential future health issues. To do this, it’s crucial to stay up to date on current treatment standards in the United States — and that starts with turning to the American Diabetes Association (ADA), which releases its Standards of Medical Care each year. What Are the ADA Standards of Care and Why Should You Care? In the ADA’s latest guidelines, released online in December 2017, the organization lists updates in areas related to heart disease and diabetes, new health technology, and more. The standards reflect the latest evidence available to help improve care and health outcomes in people with diabetes, says William T. Cefalu, MD, the chief scientific, medical, and mission officer at the ADA who is based in New Orleans, Louisiana. “The new evidence that has been available this year from published work has been incredible,” Dr. Cefalu says. Although the Standards of Medical Care are primarily geared toward the healthcare community, your diabetes management can benefit if you know about them, says Robert A. Gabbay, MD, PhD, the chief medical officer of the Joslin Diabetes Center in Boston. Following is everything you need to know about the new guidelines if you or a family member has type 1 diabetes, type 2 diabetes, or gestational diabetes. What the 2018 ADA Standards of Medical Care Say Here are some of the major changes and Continue reading >>

Children's Diabetes Foundation 2018 Practical Ways To Achieve Targets In Diabetes Care - Children's Diabetes Foundation

Children's Diabetes Foundation 2018 Practical Ways To Achieve Targets In Diabetes Care - Children's Diabetes Foundation

Registration information will beavailable later this fall This course is designed to help healthcare providers caring for patients with diabetes, including but not limited to, endocrinologists/diabetes specialists, internists, pediatricians, family physicians, physician assistants, medical residents, fellows, nurse practitioners, nurses, dietitians and certified diabetes educators. During the course of this four-day conference, we will emphasize the challenges in day-to-day management of diabetes and practical ways to overcome those hurdles, specifically using new technologies. The discussions will also focus on causes of obesity in type 2 diabetes, new therapeutic options and ways of tackling and managing obesity along with insulin resistance. The participants will have an opportunity to participate in an intimate Meet the Peers session (MDs, RNs, and educators) as well and ask a patient/provider questions in an open-discussion. For type 1 diabetes, there will be a special session on upcoming Closed Loop technologies and how to better implement them in everyday care. In addition, the deliberations will include recent data analysis of SMBG and type 2 diabetes from the ACCORD study and ways to reduce hypoglycemia in both type 1 and type 2 diabetes. The emerging markers and immunology interventions for treatment of type 1 diabetes will be discussed. Upon completion of the program, the participant should be able to: Define hypoglycemia and recognize early warnings; Analyze the management of comorbidities with diabetes; Assess diabetes care costs and health economics; Specify practical ways to introduce new therapies and technologies in Type 1 Diabetes; Specify practical ways to initiate insulin for Type 1 and Type 2 Diabetes. Continue reading >>

Ada Releases 2018 Standards Of Care For Diabetes

Ada Releases 2018 Standards Of Care For Diabetes

The American Diabetes Association (ADA) has released their annual Standards of Medical Care in Diabetes for 2018, highlighting several updated recommendations for diabetes care and management. Based on current research findings, the standards offer comprehensive practice evidence-based recommendations. The updated guidelines address the use of the medications with potential cardiovascular (CV) benefit. Other areas addressed include diabetes screening, technology, and A1C tests. Some of the most notable changes are summarized below. Cardiovascular Disease and Diabetes New guidelines incorporate the use of diabetes drugs with known cardiovascular benefit. For adults with type 2 diabetes and heart disease, the ADA recommends that, after lifestyle management and metformin, health care providers should include a medication proven to improve heart health. In the clip below, Dhiren Patel, PharmD, discusses the importance of the new recommendations for diabetes care, including the use of diabetes medications with CV risk. All hypertensive patients with diabetes are encouraged to monitor their blood pressure at home to help identify potential discrepancies between office vs. home blood pressure, and to improve medication-taking behavior, according to the guidelines. The new ADA standards also continue with the existing hypertension definition, as opposed to the American College of Cardiology’s recently updated blood pressure guidelines. The ADA’s guidelines state that most adults with diabetes and hypertension should have a target blood pressure of <140/90 mmHg and that risk-based individualization lowers targets, such as 130/80 mmHg, may be appropriate in some patients. In the clip below, Dhiren Patel, PharmD, discusses the importance of the new recommendations for diabetes Continue reading >>

More in diabetes